Novartis reported Phase III data showing its antimalarial combination GanLum (ganaplacide + lumefantrine) met the primary non‑inferiority endpoint versus the artemisinin‑based standard of care across a large trial in sub‑Saharan Africa. The company said cure rates cleared WHO thresholds, and analyses indicate activity against drug‑resistant parasite strains. The Phase III study enrolled patients across multiple countries and demonstrated clinical and parasitological efficacy with transmission‑blocking potential. Novartis will move quickly toward regulatory submissions and WHO review to position GanLum as a first new antimalarial in decades aimed at curbing emergent artemisinin resistance. Public‑health stakeholders will watch safety, cost, and deployment logistics closely; if regulators and WHO endorse the regimen, GanLum could reshape national treatment policies and partner programs targeting resistance hotspots.